Well Referenced

Tag: TACT trial

Possible differential benefits of edetate disodium in post-myocardial infarction patients with diabetes treated with different hypoglycemic strategies in the Trial to Assess Chelation Therapy (TACT)

This study analyzed data from the Trial to Assess Chelation Therapy (TACT) to evaluate whether edetate disodium chelation therapy provided different cardiovascular benefits based on the hypoglycemic treatment used by post-myocardial infarction (MI) patients with diabetes. Among 631 diabetic patients, those receiving insulin therapy experienced a significant reduction in major

Read More »
June 26, 2025 No Comments

Are concerns about reliability in the trial to assess chelation therapy fair grounds for a hasty dismissal?: An alternative perspective

This editorial discusses the concerns surrounding the reliability of the Trial to Assess Chelation Therapy (TACT), particularly regarding the use of EDTA-based chelation therapy for cardiovascular disease in diabetic patients with a history of myocardial infarction. The author argues that, despite methodological criticisms, the trial’s findings should not be dismissed

Read More »
June 26, 2025 No Comments

Chelation therapy to prevent diabetes-associated cardiovascular events

The article reviews the effectiveness of chelation therapy, specifically using disodium ethylene diamine tetraacetic acid (EDTA), in treating cardiovascular disease (CVD) in diabetic patients. The Trial to Assess Chelation Therapy (TACT) demonstrated that chelation therapy significantly reduced cardiovascular events and mortality, especially in diabetic post-myocardial infarction (MI) patients. The mechanism

Read More »
June 26, 2025 No Comments

EDTA chelation reappraisal following new clinical trials and regular use in millions of patients: review of preliminary findings and risk/benefit assessment

This review article reappraises the clinical use of EDTA chelation therapy, highlighting its effectiveness in removing toxic metals such as lead, cadmium, nickel, and aluminum. Based on recent clinical trials, EDTA therapy showed benefits such as a 50% reduction in urinary lead levels and improved systolic blood pressure in cardiovascular

Read More »
June 26, 2025 No Comments

EDTA chelation therapy meets evidence-based medicine

This article reviews the effectiveness of EDTA chelation therapy in treating cardiovascular disease, particularly for patients with diabetes and coronary artery disease. It highlights the results of the Trial to Assess Chelation Therapy (TACT), which demonstrated that EDTA can reduce cardiovascular events, improve circulation, and decrease arterial plaque, especially in

Read More »
June 26, 2025 No Comments

Important News Flash For Natural Medicine – TACT Trial

The Trial to Assess Chelation Therapy (TACT) was a seven-year study evaluating the effectiveness of an EDTA-based chelation regimen in patients aged 50 and older who had previously experienced a myocardial infarction. The study demonstrated that EDTA chelation therapy significantly reduced the composite risk of major cardiovascular events—including death, reinfarction,

Read More »
June 26, 2025 No Comments